Table 1.
Patient characteristics and CR/CRi rate. Abbreviations: allo-HCT, allogeneic hematopoietic cell transplantation; AML, acute myeloid leukemia; HMA, hypomethylating agents; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms; R/R, relapsed/refractory, CR, complete remission, CRi, CR with incomplete count recovery
| Number (%) | CR/CRi rate | P-value | |
|---|---|---|---|
| Median Age (range) | 59 (18–81) | ||
| Age | |||
| ≥ 60 | 44 (49) | 24 (55) | 0.14 |
| < 60 | 46 (51) | 17 (37) | |
| Sex | |||
| Male | 46 (51) | 18 (39) | 0.29 |
| Female | 44 (49) | 23 (52) | |
| AML type | |||
| De novo | 58 (64) | 29 (50) | 0.36 |
| Therapy-related | 10 (11) | 5 (50) | |
| Secondary | 22 (24) | 7 (32) | |
| MDS | 11 (50) | ||
| MPN | 7 (32) | ||
| MDS/MPN | 4 (4) | ||
| 2017 ELN Genetics Risk | |||
| Favorable/Intermediate | 31 (34) | 21 (68) | 0.004 |
| Adverse | 59 (66) | 20 (34) | |
| Prior allo-HCT | |||
| Yes | 26 (29) | 12 (46) | 1.00 |
| No | 64 (71) | 29 (45) | |
| Prior HMA | |||
| Yes | 46 (51) | 19 (41) | 0.53 |
| No | 44 (49) | 22 (50) | |
| Prior lines of therapy | |||
| Median (range) | 2 (1–8) | ||
| ≤ 2 | 57 (63) | 29 (51) | 0.20 |
| >2 | 33 (37) | 12 (36) | |
| HMA type and duration in combination with venetoclax | |||
| Azacitadine | 9 (10) | 3 (33) | 0.78 |
| Decitabine | 81 (90) | 38 (47) | |
| 5 days | 33 (41) | 15 (46) | |
| 10 days | 48 (59) | 23 (48) |
*
Based on chi-square or Fisher’s exact test whenever appropriate